<DOC>
	<DOC>NCT01022671</DOC>
	<brief_summary>A phase II study is conducted to determine the efficacy and safety of a single agent Camtobell inj.(belotecan) on a weekly schedule in locally advanced or metastatic non-small cell lung cancer patients previously treated with chemotherapy. The usefulness of the this regimen is evaluated by response rate, median survival time, progression free survival and duration of response.</brief_summary>
	<brief_title>Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Belotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>19 Years and older Histologically or cytologically confirmed locally advanced or metastatic NSCLC(Stage IIIB or IV) ≥ one measureable or evaluable lesion, &lt;25% of the bone marrow had been irradiated prior platinum based chemotherapy ECOG PS ≤ 2 Life expectancy &gt; 3 months Adequate organ function: hematology: ANC ≥ 1.5×109/L, Platelet ≥ 100×109/L, hemoglobin ≥ 9.0g/dL hepatic: total bilirubin ≤ 1.5×ULN, AST/ALT ≤ 2.0×ULN, ALP ≤2.0×ULN renal: serum creatinine ≤ 1.5×ULN Signed a written informed consent Active infection Symptomatic brain lesion Any other type of cancer during the previous 5 years except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix Severe concurrent diseases Prior anticancer therapy within 4 weeks before enroll Active pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Belotecan</keyword>
	<keyword>Camtobell inj</keyword>
	<keyword>NSCLC</keyword>
</DOC>